About the Company
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
244
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $REPL News
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
Replimune Group, Inc. (REPL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
Shares of Replimune Group, Inc. (REPL) have gained 16.4% over the past four weeks to close the last trading session at $9.03, but there could still be a solid upside left in the stock if short-term ...
Replimune Group (NASDAQ: REPL)
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates ...
Positive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials
Replimune Group (REPL) Company Description: Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through ...
Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
Warning! GuruFocus has detected 2 Warning Sign with REPL. On February 8, 2024, Replimune Group Inc (NASDAQ:REPL) released its 8-K filing, detailing the financial results for the fiscal third ...
Replimune Group Inc 7R8
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Replimune Group Inc (REPL)
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic ...
Replimune Group Inc REPL
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Replimune Group Inc (REPL)
Investing.com - Replimune (NASDAQ: REPL) reported third quarter EPS of $-0.77, $0.12 better than the analyst estimate of $-0.89. Revenue for the quarter came in at $0.00 versus the ...
Loading the latest forecasts...